Medullary Colonic Carcinoma

Prognostic Factors Clinical Trial

— MEDCCR  

Official title:

Medullary Colonic Carcinoma

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05184153
• Other study ID #: 87RI20_0072 (MEDCCR)
• Status: Completed
• Start date: March 3, 2020
• Est. completion date: September 1, 2021

Study information

• Verified date: September 2021
• Source: University Hospital, Limoges
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Retrospective cohort of 10 cases of colonic adenocarcinoma of medullary type, operated between 2000 and 2020 at the University Hospital of Limoges. Collection of relevant data for this rare entity. Subgroup analysis in search of prognostic factors. Comparison of the data from our cohort with those from the literature.

Description:

Colorectal cancer (CRC) is the third most common cancer in the world after breast and prostate cancer (1). It is also the second most common cause of cancer death in France (2). Most CRCs are adenocarcinomas. However, there is a distinct subtype of adenocarcinoma of relatively recent recognition, called medullary carcinomas (MC). Its recent recognition as a distinct entity (3) has made it difficult to study the epidemiologic characteristics of this cancer, with little population-based data. The largest cohort studied in the literature is from a US sample of 74 patients seen between 1973 and 2006 (4). The main objective of this French retrospective study is to highlight some common features in this group of patients with medullary colorectal cancers, thus improving our knowledge of this cancer subtype and in particular its prognosis.

Medullary colorectal cancer is a type of cancer with a prognosis of its own, probably different from the most common histological entity, colorectal adenocarcinoma.

This is a retrospective study a cohort of 10 cases of colonic adenocarcinoma of medullary type, operated between 2000 and 2020 at the University Hospital of Limoges. A collection of relevant data was realised for the subgroup analysis in search of prognostic factors for this rare entity as well as a comparison of the data from this cohort with those from the literature.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 10
• Est. completion date: September 1, 2021
• Est. primary completion date: December 19, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• Pathological diagnosis of colorectal adenocarcinoma of medullary type between 2000 and 2020

Exclusion Criteria:

• Absence of anatomopathological confirmation on the surgical specimen

Related Conditions & MeSH terms

• Carcinoma
• Prognostic Factors
• Survival Analysis

Locations

Country	Name	City	State
France	Service de Chirurgie Digestive et Endocrinienne du CHU de Limoges	Limoges

Sponsors (1)

Lead Sponsor	Collaborator
University Hospital, Limoges

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Survival	Number of days between diagnosis and death	Through study completion in April 2021
Secondary	Progression	Number of days between first surgery and appearance of metastases	Through study completion in April 2021